The stock of BioNexus Gene Lab Corp (NASDAQ: BGLC) has increased by 21.20 when compared to last closing price of 2.17. Despite this, the company has experienced a 12.11% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-07 that KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation.
Is It Worth Investing in BioNexus Gene Lab Corp (NASDAQ: BGLC) Right Now?
BGLC has 36-month beta value of 1.72.
The public float for BGLC is 1.10M, and currently, short sellers hold a 10.58% ratio of that float. The average trading volume of BGLC on April 14, 2025 was 127.56K shares.
BGLC’s Market Performance
BGLC stock saw a decrease of 12.11% in the past week, with a monthly decline of -25.07% and a quarterly a decrease of -19.57%. The volatility ratio for the week is 33.67%, and the volatility levels for the last 30 days are 16.66% for BioNexus Gene Lab Corp (BGLC). The simple moving average for the last 20 days is -4.00% for BGLC stock, with a simple moving average of -29.60% for the last 200 days.
BGLC Trading at -19.61% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.70% of loss for the given period.
Volatility was left at 16.66%, however, over the last 30 days, the volatility rate increased by 33.67%, as shares sank -24.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.06% lower at present.
During the last 5 trading sessions, BGLC rose by +12.11%, which changed the moving average for the period of 200-days by -45.03% in comparison to the 20-day moving average, which settled at $2.74. In addition, BioNexus Gene Lab Corp saw -5.97% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.13 for the gross margin
The net margin for BioNexus Gene Lab Corp stands at -0.1. The total capital return value is set at -0.12. Equity return is now at value -9.87, with -8.38 for asset returns.
Based on BioNexus Gene Lab Corp (BGLC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.68. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -56.5.
Currently, EBITDA for the company is -2.49 million with net debt to EBITDA at 5.14. When we switch over and look at the enterprise to sales, we see a ratio of 0.09. The receivables turnover for the company is 6.5for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To put it simply, BioNexus Gene Lab Corp (BGLC) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
